Evotec AG (Frankfurt Stock Exchange, Prime Standard, ISIN: DE 000 566480 9, WKN 566480) today announced that the stockholders of Renovis, Inc. (NASDAQ: RNVS) approved the adoption of the merger agreement with Evotec at a special meeting of Renovis stockholders held today. There is no requirement for Evotec to obtain approval of the transaction by its stockholders. The acquisition is expected to close by May 5, 2008.

In connection with the acquisition, Renovis stockholders will receive 0.5271 American Depositary Shares, or ADSs, of Evotec for each outstanding share of Renovis common stock. Each Evotec ADS represents two ordinary shares of Evotec, such that each outstanding share of Renovis common stock will be exchanged for ADSs representing 1.0542 Evotec ordinary shares. As a result, Evotec will issue an aggregate of 34,970,268 new Evotec shares underlying the ADSs issued to Renovis stockholders. The Evotec ADSs have been approved for listing on the NASDAQ Global Market under the trading symbol "EVTC". The first day of trading is expected to be on or about May 5, 2008 and the ADSs will trade on a "when issued" basis under the symbol "EVTCV" until they are eligible for normal trade settlement, currently anticipated to be within two weeks of the acquisition.

Contact: Anne Hennecke, SVP, Investor Relations & Corporate Communications, Evotec AG, Schnackenburgallee 114, 22525 Hamburg, Germany, Phone: +49.(0)40.560 81-286, anne.hennecke@evotec.com